摘要目的:了解吗替麦考酚酯（MMF）眼部不良事件（AE）风险信号，为该药临床安全应用提供参考。方法:检索美国FDA不良事件报告系统（FAERS）数据库，收集2004年第1季度至2022年第3季度以MMF为首要怀疑药物的AE报告。根据《国际医学用语词典》（MedDRA）24.0版的系统器官分类（SOC）和首选术语（PT）对AE进行分类统计，筛选眼部AE。采用3种频数法[报告比值比法（ ROR）、比例报告比值法（ PRR）、贝叶斯置信传播神经网络法（BCPNN）]和多项伽玛-泊松分布缩减（MGPS）法进行眼部AE风险信号挖掘。对MMF眼部AE报告信息和AE风险信号进行描述性分析。 结果:共收集到以MMF为首要怀疑药物的眼部AE 402例，涉及402例患者、31个PT、5个SOC。402例AE由33个国家上报，有临床结局记录者283例，包括死亡32例（11.3%）、致残或失明142例（50.2%）、威胁生命14例（4.9%）、住院或住院时间延长95例（33.6%）。频数法检测结果显示31个PT均为风险信号，MGPS法检测发现其中22个PT为风险信号。31个PT均未在药品说明书中记载，AE报告数排在前5位的PT为失明（136例）、巨细胞病毒性脉络膜视网膜炎（37例）、葡萄膜炎（34例）、眼内炎（29例）、坏死性视网膜炎（22例）。4种方法检测的信号强度排名基本一致，信号强度居前5位的PT分别为眶尖综合征[ ROR=55.84， PRR=55.83，信息成分( IC)=5.58，贝叶斯几何均数( EBGM)=47.71]、象限盲（ ROR=43.22， PRR=43.21， IC=5.26， EBGM=38.21）、病毒性视网膜炎（ ROR=40.13， PRR=40.13， IC=5.16， EBGM=35.78）、视盘模糊（ ROR=40.13， PRR=40.13， IC=5.16， EBGM=35.78）、匐行性脉络膜炎（ ROR=31.07， PRR=31.07， IC=4.83， EBGM=28.41）。 结论:MMF治疗中发生的眼部AE临床表现多样，且均未被说明书记载；临床结局差，可导致失明，临床应予警惕。

abstractsObjective:To understand the risk signal of ocular adverse events (AE) related to mycophenolate mofetil (MMF) and to provide reference for the safe clinical use of this drug.Methods:The US FDA Adverse Event Reporting System database was searched, and the AE reports on MMF as the primary suspect drug from the 1st quarter of 2004 to the 3rd quarter of 2022 were collected. AEs were counted and classified using the preferred system organ class (SOC) and preferred term (PT) of Medical Dictionary for Regulatory Activities version 24.0, and ocular AEs were screened out. The ocular AE risk signals were explored using 3 frequency methods, including reporting odds ratio (ROR) method, proportional reporting ratio (PRR) method, and Bayesian confidence propagation neural network method, and the multi-item gamma-Possion shrinker (MGPS) method. The information of the ocular AE reports and AE risk signals of MMF were analyzed descriptively. Results:A total of 402 cases of ocular AE with MMF as the primary suspect drug were collected, which involved 402 patients, 31 PTs and 5 SOCs. The 402 AE cases were reported among 33 countries, 283 of which had clinical outcome records, including death in 32 cases (11.3%), disability or blindness in 142 cases (50.2%), life-threatening in 14 cases (4.9%), and hospitalization or prolonged hospitalization in 95 cases (33.6%). Results of the frequency method showed that all 31 PTs were risk signals, while the results of the MGPS method manifested that 22 PTs were risk signals. None of the 31 PTs were recorded in the drug labels. The top 5 PTs in the number of AE reports were blindness (136 cases), cytomegalovirus chorioretinitis (37 cases), uveitis (34 cases), endophthalmitis (29 cases), and necrotising retinitis (22 cases). The ranking of signal intensity showed by the 4 methods was similar. The top 5 PTs with the high signal intensity were orbital apex syndrome [ ROR=55.84, PRR=55.83, information component ( IC)=5.58, empirical Bayesian geometric mean ( EBGM)=47.71], quadrantanopia ( ROR=43.22, PRR=43.21, IC=5.26, EBGM=38.21), retinitis viral ( ROR=40.13, PRR=40.13, IC=5.16, EBGM=35.78), optic discs blurred ( ROR=40.13, PRR=40.13, IC=5.16, EBGM=35.78), and serpiginous choroiditis ( ROR=31.07, PRR=31.07, IC=4.83, EBGM=28.41). Conclusions:The clinical manifestations of ocular AE during MMF treatment are diverse, and none of them are recorded in the drug label. The clinical outcomes are poor and can lead to blindness, which should be vigilant in clinical practice.